HKSE · 2289.HK
Charmacy Pharmaceutical Co., Ltd.
HK$5.49-HK$0.01 (-0.09%)
Charmacy Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.81% below the high.
Loading market information…
HKSE · 6118.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Austar Lifesciences Limited’s quoted price sits in the lower half of its reported 52-week range, 59.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Austar Lifesciences Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Austar Lifesciences Limited functions as an investment holding company, delivering integrated engineering and technology solutions to pharmaceutical production facilities and research institutions globally, with a significant presence in Mainland China. Its business activities are structured across six primary divisions: liquid and bioprocessing systems; controlled environment and automated monitoring systems; powder and solid material handling systems; Good Manufacturing Practice (GMP) adherence services; life science expendables; and the brokerage and supply of pharmaceutical machinery. The company's product portfolio is extensive, including systems for pharmaceutical water, liquid preparation, and bioprocessing; powder and solid processing units; clean utility infrastructure; and advanced cleanroom technology. They also supply automated control and monitoring systems, freeze-dryers, sterile filling equipment, and visual inspection apparatus. Furthermore, Austar provides products for pharmaceutical contamination control, aseptic packaging and containment, biosafety and lab animal equipment and consumables, single-use bioprocess components, and offers holistic laboratory setup solutions. Beyond its product offerings, Austar Lifesciences extends a wide array of professional services, such as design and engineering, quality risk management, expert consultation, research and development assistance, process optimization, and digitalization strategies. The company also offers post-sale support, on-site services, system upgrades, facility relocation guidance, and comprehensive asset management. Additionally, it serves as an agent and distributor for pharmaceutical equipment, providing associated assembly and pre-assembly services. Established in 1991, Austar Lifesciences Limited is headquartered in Shanghai, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:47 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$5.49-HK$0.01 (-0.09%)
Charmacy Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.81% below the high.
HK$1.74+HK$0.06 (+3.57%)
Guangdong Kanghua Healthcare Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 23.68% below the high.
HK$0.63-HK$0.02 (-2.34%)
Zhongzhi Pharmaceutical Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 36.22% below the high.
HK$0.71+HK$0.03 (+3.65%)
Vincent Medical Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 34.86% below the high.
HK$1.39+HK$0.01 (+0.72%)
Suzhou Basecare Medical Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 47.55% below the high.
HK$0.62-HK$0.03 (-3.88%)
Yunkang Group Limited’s quoted price sits in the lower half of its reported 52-week range, 50.4% below the high.
HK$0.33-HK$0.01 (-2.94%)
Modern Chinese Medicine Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 89.88% below the high.
HK$0.17-HK$0.01 (-5.17%)
Rainmed Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
